Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy
about
Tyrosine Kinase Inhibitors for the ElderlyAfatinib in Non-Small Cell Lung CancerDrug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the LiteratureCancer: we should not forget the pastTargeted Lung Cancer Treatments and Eye MetastasisA multifactoral analysis of 1452 patients for smoking sensation. An outpatient lab experience.Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series."Liquid elbows" due to afatinib administration.Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.Enhancement of Intratumoral Chemotherapy with Cisplatin with or without Microwave Ablation and Lipiodol. Future Concept for Local Treatment in Lung Cancer.Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?DDMC-p53 gene therapy with or without cisplatin and microwave ablation.Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.Biopsy testing in an inoperable, non-small cell lung cancer population-a retrospective, real-life study in SwedenPhase I study of afatinib combined with nintedanib in patients with advanced solid tumours.Clinical Challenges to Current Molecularly Targeted Therapies in Lung CancerDownregulation of TFAM inhibits the tumorigenesis of non-small cell lung cancer by activating ROS-mediated JNK/p38MAPK signaling and reducing cellular bioenergetics.Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer and Eye Metastasis: Disease Relapse or a New Entity?Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer.Regulation of cellular iron metabolism and its implications in lung cancer progression.Polymer-based platforms by electric field-assisted techniques for tissue engineering and cancer therapy.Nab-paclitaxel as First Line Treatment for NSCLC in Elderly Patients More Than 75 Years Old.Enhancement of Aerosol Cisplatin Chemotherapy with Gene Therapy Expressing ABC10 protein in Respiratory System.Trends in phase III randomized controlled clinical trials on the treatment of advanced non-small-cell lung cancerInhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment.Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three casesEGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50.Fluorofenidone Inhibits the Proliferation of Lung Adenocarcinoma CellsImmunotherapy "Shock" a case series of PD-L1 100% and pembrolizumab first-line treatment.Second-line afatinib administration in an elderly patient with squamous cell carcinoma.MicroRNA-133b inhibits the migration and invasion of non small cell lung cancer cells via targeting FSCN1.Immunotherapy "Shock" with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma.A new mode of ventilation for interventional pulmonology. A case with EBUS-TBNA and debulking.Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50.Psoriatic arthritis due to nivolumab administration a case report and review of the literature.Tumor heterogenicity: multiple needle biopsies from different lesion sites-key to successful targeted therapy and immunotherapy.
P2860
Q26748567-87C81A57-3369-4177-8628-98E2F91DFF98Q26749005-70F1D6A8-776E-452A-A303-53FFE6C9E385Q26766244-CBF45B03-81DC-4ACE-AC35-85F26899887CQ26828818-B4E941CA-640F-4F21-823C-E2AD78F495E8Q33566410-5C0F64F4-C43F-4993-AA36-4EF20981D631Q33634980-2498DF21-C9DD-4268-8857-CA66A6CD049DQ33763622-4D2FECA4-0F7E-462F-8E78-9926F43F6F00Q33855130-FF96A6B1-AE6F-46F4-AF2B-64015A9132F3Q34404209-C520C0B2-6DFC-40AE-BB8D-0D5F7189126AQ35051258-6ACE373E-8429-415F-9603-87FCECA2FE63Q35148094-1D395BC3-AEDF-4008-9A8C-9C89006FF8E9Q35654976-DFEC1CC3-9B34-4A01-87E8-B0071EBA1DC1Q36333164-10CE1717-7288-482B-93C1-5CDDFE9FA5DFQ36437538-3CD30747-C3AA-4C9D-8316-AC092FA1925FQ36750974-3AEA7710-F515-4932-865F-63879AD23933Q36972377-FFD3E1F5-A856-485D-9F11-57AF311E4D74Q36998321-B06BA2FD-1F13-4857-92D4-1F1AC0ABAF6CQ37694116-C3A14390-C127-43AE-8E65-0736E3A9814CQ37706510-DCB125B1-9948-485A-83AA-623F8ECB4F02Q38214914-F5FBFD90-36AF-4A11-B368-55C0AC52DA74Q38285284-7A96F58A-C5E0-4444-A2BB-0E432E8EA1D2Q38641997-5FA71CDC-3EC8-4603-A421-A94843311B77Q38689201-496387EF-901E-45C1-9071-CFF80E0398C4Q38905885-42791873-4D3B-4C6C-811C-A59CE557FAB1Q39109514-881EE6DF-F73A-4503-AEB3-1D51BCAF944EQ41072491-A81D3D92-94F7-4501-8448-3388A98E7F77Q41107790-FAC11025-5BE7-4CFE-9829-7561ABD117A1Q41396331-6E66176A-DDAD-4142-BEF2-47DD9AC95F50Q41563422-5ECEBF34-3196-4EFF-BE5B-9FF31BAE66E2Q41823165-D91F1937-F45C-4F3A-9046-12651901A9ADQ42370547-D9C834F7-77CB-46A9-A69C-0CA140FE49A2Q47105617-BB0C2486-DCDF-4A72-86A5-19F0AFA2C6CDQ47682234-3FAB2203-6417-4AFA-8868-6B4C2B7B31F9Q50345931-874A9D77-4505-45B7-B79C-2A6C0FEEFA65Q52659187-37DD3293-D90E-4E35-8367-8A5F0063365BQ55220927-A3062B76-A228-46CF-97F9-76CC762FDC91Q55324052-20759D8A-3876-470D-888B-4B81A2A2F736
P2860
Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Molecular Targeted Drugs and B ...... Role of Individualized Therapy
@en
Molecular Targeted Drugs and B ...... ole of Individualized Therapy.
@nl
type
label
Molecular Targeted Drugs and B ...... Role of Individualized Therapy
@en
Molecular Targeted Drugs and B ...... ole of Individualized Therapy.
@nl
prefLabel
Molecular Targeted Drugs and B ...... Role of Individualized Therapy
@en
Molecular Targeted Drugs and B ...... ole of Individualized Therapy.
@nl
P2093
P2860
P356
P1433
P1476
Molecular Targeted Drugs and B ...... Role of Individualized Therapy
@en
P2093
Antonis Papaiwannou
Dionysios Spyratos
Ioannis Kioumis
J Francis Turner
Kaid Darwiche
Kalliopi Domvri
Konstantinos Porpodis
Konstantinos Zarogoulidis
Lutz Freitag
Paul Zarogoulidis
P2860
P304
P356
10.7150/JCA.7734
P577
2013-11-23T00:00:00Z